US EditionStudy spruiks Firebrick's Nasodine spray as 'effective treatment for common cold'
Summary by themarketonline.com.au
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Study spruiks Firebrick's Nasodine spray as 'effective treatment for common cold'
A long-run study looking into leading Firebrick Pharma (ASX:FRE) product Nasodine has suggested the nasal spray can be an effective treatment for the common cold following a dive into the company’s Phase III trials. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. The study, published in the open-access journal Frontiers in Medicine, suggeste…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
